<DOC>
	<DOC>NCT01207648</DOC>
	<brief_summary>The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon [IFN]-beta-1a) in children and adolescents, using information already recorded in medical records. The study duration is 13 July 2010 (first data collected) to 13 July 2011 (last data collected). In this study, Data of the subjects evaluated between 1997 and 2009 was observed.</brief_summary>
	<brief_title>Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Received one or more injections of Rebif® for treatment of a demyelinating event Be younger than 18 years of age at time of Rebif® treatment initiation Rebif® therapy must have been initiated before June 30, 2009 No exclusion criteria are applied</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Interferon beta 1a</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Demyelinating Autoimmune Diseases, CNS</keyword>
	<keyword>Autoimmune Diseases of the Nervous System</keyword>
	<keyword>Retrospective Cohort Study</keyword>
</DOC>